Inhalation Sciences (ISAB) has entered a collaboration with Germany-based Actarmo Medical for respiratory drug development services.
The deal will expand the service offerings of the companies within the inhaled therapeutics market and enhance their capabilities across the respiratory drug development chain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The alliance will provide a more comprehensive end-to-end service offering. This includes preclinical in vivo and in vitro pharmacokinetic studies, the testing of devices and the complete development of inhalation combination assets.
The synergy of their services presents a significant competitive edge for both companies and their collective client base in the inhalation sector.
ISAB’s strategic shift towards services as its primary revenue source is further supported by the partnership.
The company’s business area, inhalation research services, will benefit from an expanded ability to serve pharmaceutical and medical device clients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe total addressable market of the combined offerings is projected to rise by 30%, passing €630m ($685m).
Actarmo Medical brings to the partnership a well-established clientele and professional expertise in formulation development, MDR [medical device reporting] consultancy, analytical testing and consultancy for inhaler delivery products.
ISAB focuses on preclinical pharmacokinetic studies to assess the inhaled compounds’ behaviour early in the development process. This research is vital for improving prediction accuracy in clinical trial outcomes.
The deal will also involve joint selling and commercialisation efforts for the combined service offering.
Actarmo Medical CEO Thomas Weuthen stated: “Actarmo Medical and ISAB work in complementary areas of drug development and the combined range of services will be very appealing to customers, simplifying their inhalation drug product development process.
“ISAB’s services do fill a gap we have seen several times within our projects, and we are happy to now work closely with ISAB. This collaboration brings us new customers which we did not address until now and I am really looking forward to this cooperation.”
